Swedish specialist pharmaceutical company Orexo has reported positive results from its Retrospective Evaluation of Zubsolv Outcomes A Longitudinal View (REZOLV) retrospective study of Zubsolv to treat opioid dependence.
Zubsolv is composed of buprenorphine and naloxone and formed as a sublingual tablet (CIII) to treat opioid dependence.
With an enrolment of 1,080 patients, the REZOLV was the largest retrospective study, completed last month in the US to optimise treatment of opioid dependence.
The study intended to determine the efficacy of Zubsolv in treating opioid dependence.
Results validated the treatment efficacy of Zubsolv in reducing opioid dependence within 77.6% of the enrolled patients.
Orexo president and CEO Nikolaj Sørensen said: “The finalisation of the REZOLV study is one more important milestone we have reached during the summer.
“In June we signed an ex-US license agreement with Mundipharma, followed by new legislation in the US with the potential to significantly improve access to treatment with Zubsolv and now we have finished the REZOLV study.
“We have seen a positive uptake in the use of Zubsolv in the US this summer, and with the REZOLV study we strengthen our ability to engage with physicians and payers in optimising and improving access to treatment of opioid dependence.”
The data generated from the study can aid the clinicians in the identification and rationalisation of some of the key factors related to a successful treatment of opioid dependence.
